🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ICYMI—May is #ALSAwarenessMonth ❤️ #ALS is a devastating disease, with cases projected to rise 70% by 2040, posing significant challenges for research. At Unlearn, we’re addressing these challenges with AI-generated #digitaltwins that forecast the complex progression of this

We’re excited to join the 4th Annual ALS Drug Development Summit in Boston in just a few days! Don’t miss our presentation, “AI-Generated Digital Twins in ALS: Improving Confidence in Early-Stage Studies,” in collaboration with ProJenX, and our poster, “Applications of Digital

Unlearn’s Co-founder and Chief Scientific Officer, Jon Walsh, was recently interviewed by Pharma Life Sciences to talk about how AI-generated #digitaltwins of study participants are reshaping #clinicaltrials. He highlights the many benefits digital twins already provide,

The ALS Drug Development Summit underscores the transformative potential of collaboration and innovation in advancing treatments for #neurodegenerativediseases. We were proud to contribute through two key initiatives: our presentation, "AI-Generated Digital Twins in ALS:

🧠 Early #ALS trials present significant challenges, with limited patient populations and no validated biomarkers, complicating the assessment of drug efficacy. At the ALS Drug Development Summit, we co-presented alongside ProJenX, highlighting how Unlearn’s ALS DTG model has

Building on our commitment to advancing #ALS research, we’re proud to continue driving progress at #ENCALS2025. Join us for our poster presentation, “Enhancing Prognostic Value of Plasma NfL for Amyotrophic Lateral Sclerosis (ALS) Through Digital Twins to Improve Trial

#UnlearnerSpotlight 🚀 “It’s incredibly meaningful to be part of a team working toward something bigger than ourselves—improving clinical trials to help real people. On top of that, I’m constantly inspired by the brilliant minds around me."

Attending #ENCALS2025? Don’t miss our poster presentation, “Enhancing Prognostic Value of Plasma NfL for Amyotrophic Lateral Sclerosis (ALS) Through Digital Twins to Improve Trial Efficiency.” 🗓 Thursday, June 5 | 🕒 4:30–5:30 PM | 📍 Poster Session B Connect with our team to

🎉 We’re excited to join Bristol Myers Squibb’s exclusive event, 'Digital Breakthrough for Pharma Summit 2025' on June 3! Our co-founder and Machine Learning Scientist, Aaron Smith, will be a featured speaker, presenting “AI-Powered Digital Twins: Practical Applications in Clinical

🧠 Did you know 500,000 new cases of Alzheimer's disease are diagnosed each year? June is Alzheimer’s and Brain Awareness Month, a time to bring visibility and drive action towards curing this debilitating disease. We’re proud to be a part of the fight, using #digitaltwins to

“We’re at an inflection point. Digital twins are no longer theoretical. They’re working, they’re trusted, and they’re delivering value today.” — Aaron Smith in the Forbes article, "The Future Of Drug Trials Might Be Virtual AI Patients" by Tor Constantino, MBA | 🚀 bit.ly/457W20C

The FDA has launched its new generative #AI tool, Elsa, to help optimize workflows across the agency. Hear from our co-founder & Chief Scientific Officer, Jon Walsh, on the implications for #drugdevelopment: 💊 bit.ly/4jBL1It

Building on our dedication to advancing #ALS research, we were proud to contribute to the progress showcased at #ENCALS2025 through our poster presentation, “Enhancing Prognostic Value of Plasma NfL for Amyotrophic Lateral Sclerosis (ALS) Through Digital Twins to Improve Trial

The FDA wants #AI in trials to follow a 7-step credibility framework. This whitepaper shows how we do exactly that to boost trial power without requiring additional participants. 📄 Read more: bit.ly/3ZnGvpH

👥 "Digital twins ultimately provide answers to counterfactual questions about an individual—How will their disease progress? What will likely be effects of interventions? What are the risk of significant health events?” — Aaron Smith, Unlearn co-founder and Machine Learning

🧪 The FDA’s new framework is transforming how #AI is integrated into #clinicaltrials, driving a rapid evolution in #drugdevelopment. If you're attending Drug Information Association (DIA) 2025, don't miss our co-founder and Machine Learning Scientist Aaron Smith's presentation, “Technical and

🧬 What are digital twins? AI models that predict how patients would respond to placebos, without giving them one. This means more trial participants get real treatment. Unlearn.AI's Jon Walsh explains to PYMNTS how this 75-year-old process finally gets modernized in today's

“We’re not just tweaking the system,” Jon Walsh, co-founder and Chief Scientific Officer at Unlearn, explained during a discussion hosted by PYMNTS CEO Karen Webster. “We’re re-architecting it.” 🚀 bit.ly/3HJCeXB

#UnlearnerSpotlight 🚀 “It's exciting and rewarding to get to work closely with a remarkably smart, diverse and committed group of people on a shared mission to change not just the clinical research industry, but also patients' lives.”

AI in trials is moving fast. Learn how we’re staying in step with the FDA in our latest blog. 🚀 bit.ly/3HGF8MZ